SOBRE ESTE EPISÓDIO

Inglês
Estados Unidos da América

TRANSCRIÇÃO 🔗

PESQUISAR EPISÓDIOS PASSADOS

Pesquisar episódios anteriores de Taylor & Francis.

OUTROS EPISÓDIOS NESTE PODCAST

In this interview, Imogen Locke (The Royal Marsden NHS Foundation Trust, UK) discusses the evolving role of stereotactic ablative radiotherapy (SABR) in oligometastatic and oligoprogressive breast cancer. Locke explains the distinction between these two clinical scenarios, how timing and patient s…
First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group
The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patient–doctor relationship, patient care and outcomes. The authors believe that this…
Over the past two decades, HER2-positive breast cancer has undergone a dramatic transformation in oncology. In this interview, Cristina Saura (Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Spain) reflects on witnessing this evolution firsthand, from the introduction of …
Christopher Lieu, co-director of gastrointestinal medical oncology and the associate director for clinical research at the University of Colorado Cancer Center (CO, USA) discusses the importance of biomarker testing in metastatic colorectal cancer to inform personalized patient care.
Aviso: O podcast e a arte incorporada nesta página são de Taylor & Francis Group, que é propriedade de seu proprietário e não é afiliado ou endossado por Listen Notes, Inc.